New drug cocktail aims to tackle rare blood cancer

NCT ID NCT06029309

Recruiting now Disease control Sponsor: Alvaro Alencar, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a combination of two drugs, zanubrutinib and tafasitamab, in people with mantle cell lymphoma, a rare blood cancer. The first part of the trial will find the best dose of zanubrutinib when used with tafasitamab. The second part will see how well the combination works at shrinking tumors. About 27 adults with confirmed mantle cell lymphoma will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib and tafasitamab
What this could lead to: If this combination works, it could offer a new treatment option for mantle cell lymphoma, potentially improving response rates.
What could go wrong: This is an early-phase trial with only 27 participants, so results may not apply broadly. Side effects from the drug combination are possible and the ideal dose is still being determined.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.